Browse 113 Cll Medical Studies Across 386 Cities
19 Phase 3 Trial · 1383 Cll Clinics
What Are CLL Clinical Trials?
Chronic lymphocytic leukemia (CLL) is a kind of cancer that starts in the lymphocytes (white blood cells) in the bone marrow and then goes into the blood. One characteristic of CLL is that cancer cells usually build slowly, and the disease isn’t symptomatic for a few years. That accounts for the “chronic” in “chronic lymphocytic leukemia.” Eventually, the cells spread to the liver, spleen, and lymph nodes.
There is no cure for this cancer, but CLL clinical trials focus on better treatment and management options.
Why Is CLL Being Studied Through Clinical Trials?
According to the American Cancer Society, there have been approximately 60,650 new cases of leukemia and 24,000 deaths from leukemia in 2022. Of these, 20,160 are new cases of CLL. There have also been approximately 4,410 deaths from CLL. CLL clinical trials are necessary since CLL accounts for approximately a quarter of all new cases of leukemia. In fact, for the average person, the lifetime risk of getting CLL is 1 in 175 (0.57%).
What Are the Types of Treatments Available for CLL?
CLL grows slowly, and patients don’t always need to be treated immediately. Healthcare professionals may suggest chemotherapy, targeted therapy drugs, monoclonal antibodies, or stem cell transplants, depending on when treatment is needed. Patients may need to undergo radiation therapy, surgery, or leukapheresis in more severe cases. CLL clinical trials look at promising new procedures and treatments so healthcare professionals can learn how to manage the disease better.
What Are Some Recent Breakthrough Clinical Trials for CLL?
A few recent CCL clinical trials have resulted in breakthrough research on treatment options.
2021: Triplet Therapy – A phase II clinical trial evaluated the experimental triplet therapy consisting of acalabrutinib, venetoclax, and obinutuzumab. 86% of participants showed a significant response over two years, after which no minimal residual disease (MRD) was detected in the patients’ bone marrow.
2022: Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy – In 2010, two patients with end-stage CLL received CAR T-cell therapy and were in remission. Over a decade later, activated CAR T-cells are still active in their blood, keeping the cancer at bay. This is the longest-known CLL remission after this type of therapy.
What Are Some of the Key Opinion Institutions Conducting CLL Clinical Trial Research?
The University of Texas MD Anderson Cancer Center
The MD Anderson Cancer Center is a comprehensive cancer center in Texas. In addition to being one of the original three comprehensive cancer centers in the U.S., it’s also the largest cancer center in the U.S. The center runs various CCL clinical trials to find treatments, focusing on shifting from cytotoxic chemotherapy to well-tolerated oral therapies. The MD Anderson Cancer Center’s current CCL clinical trials include those on the comparison of different dosages of ibrutinib, the efficacy of venetoclax and ibrutinib, and more.
The James – The Ohio State University Comprehensive Cancer Center
The James is a comprehensive cancer center focusing on scientific research and patient-centered care. Because it’s National Cancer Institute (NCI)-designated, it can conduct phase I and II clinical trials on novel anticancer drugs. The James’ CCL clinical trials include those focusing on ARQ 531, venetoclax, ibrutinib, and more.